Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases.

Abstract

Many Chinese patients with hematologic diseases, who need allogeneic hematopoietic stem cell transplantation (HSCT), lack a human leukocyte antigen-matched donor. To save these patients and to avoid collecting donor bone marrow graft, we adopted haploidentical peripheral blood HSCT with granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells as the grafts without ex vivo T cell depletion. Thirty-eight patients were enrolled, and they received myeloablative preconditioning. Thirty-five patients attained a successful neutrophil and platelet recovery. The median time for the neutrophil recovery was 16 days (range of 10-23 days), and the median time for the platelet recovery was 19 days (range of 10-66 days). During the follow-up at a median time of 33.1 weeks (range of 1.1-412.6 weeks), eleven (28.9 %) patients developed aGVHD grade I-II and seven (18.4 %) patients developed aGVHD grade III-IV. The incidence of cGVHD was 27.6 %, and nine (23.7 %) patients died within the first 100 days after transplantation. The cumulative survival proportions at 1 and 2 years were 52.51 ± 8.57 % and 43.76 ± 9.11 %, respectively. These results suggested that the G-CSF-primed peripheral blood stem cell grafts, without in vitro T cell depletion, could be an appropriate stem cell source for Haplo-HSCT.

• Authors: Rui-Nan Lu, Kou-Rong Miao, Run Zhang, Ming Hong, Ji Xu, Yu Zhu, Hua-Yuan Zhu, Xiao-Yan Qu, Shuai Wang, Li Wang, Lei Fan, Wen-Yi Shen, Hua Lu, Hong-Xia Qiu, Xiao-Yan Zhang, Li-Juan Chen, Wei Xu, Jian-Yong Li, Han-Xin Wu, Si-Xuan Qian
• Journal: Medical oncology (Northwood, London, England) (Med Oncol) Vol. 31 Issue 8 Pg. 81 (Aug 2014) ISSN: 1559-131X [Electronic] United States
• PMID: 25001087 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Recombinant Fusion Proteins
• Granulocyte Colony-Stimulating Factor
• Basiliximab

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal (therapeutic use)
• Basiliximab
• Female
• Graft vs Host Disease (epidemiology, prevention & control)
• Granulocyte Colony-Stimulating Factor (administration & dosage, therapeutic use)
• Haplotypes
• Hematopoietic Stem Cell Mobilization (adverse effects, methods)
• Hematopoietic Stem Cell Transplantation (adverse effects, methods)
• Humans
• Leukemia (mortality, therapy)
• Male
• Middle Aged
• Peripheral Blood Stem Cell Transplantation (methods)
• Recombinant Fusion Proteins (therapeutic use)
• Survival Analysis
• T-Lymphocytes
• Tissue Donors
• Transplantation Conditioning (methods)
• Treatment Outcome
• Young Adult